DTG/3TC

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

EffectivenessHIV-1 InfectionImmunodeficiency

76 competitors in Effectiveness

#DrugCompanyPhaseTrials

1

Kesimpta

Novartis

Phase 3

22

Mounjaro

Eli Lilly

Phase 3

13

Actos

Takeda

Phase 3

14

Elucirem

GGuerbet

Phase 3

15

Nicotine Free Cigarettes

Pfizer

Phase 3

36

Lidocain

Bayer

Phase 3

17

Botulinum Toxin a

GSK

Phase 3

18

Pneumococcal Conjugate Vaccine

Novartis

Phase 3

19

Haldol

DDePuy Orthopaedics

Phase 2

110

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

HIV Infections2 trials

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of 2-drug Injectable Regimens of VH4011499 Plus Cabotegravir in Treatment Naïve Viremic Adult Participants With HIV-1 (CINERGY)

Not yet recruiting·GSK·Phase 2·NCT07816250·200 enrolled

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)

Recruiting·GSK·Phase 2·NCT07202546·186 enrolled

First-line1 trial

Good-first: B/F/TAF As First-line ART

Recruiting·—··NCT06619288·630 enrolled

Effectiveness1 trial

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

Recruiting·IInstituto Mexicano del Seguro Social·Phase 4·NCT07031063·124 enrolled

Immunodeficiency1 trial

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting·GSK·Phase 3·NCT05917509·171 enrolled

HIV1 trial

A Phase 3b, Multicenter, Single-arm, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to DTG/3TC Single Tablet Regimen Administered Once Daily From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in People Living With HIV of at Least 50 Years of Age Who Are Virologically Suppressed

Completed·GSK·Phase 3·NCT05911360·205 enrolled

Details

Drug Info

Related News